193 related articles for article (PubMed ID: 22250605)
1. Negative impact of migraine on quality of life after 4 weeks of treatment in patients with major depressive disorder.
Hung CI; Liu CY; Yang CH; Wang SJ
Psychiatry Clin Neurosci; 2012 Feb; 66(1):8-16. PubMed ID: 22250605
[TBL] [Abstract][Full Text] [Related]
2. The impacts of migraine, anxiety disorders, and chronic depression on quality of life in psychiatric outpatients with major depressive disorder.
Hung CI; Wang SJ; Yang CH; Liu CY
J Psychosom Res; 2008 Aug; 65(2):135-42. PubMed ID: 18655858
[TBL] [Abstract][Full Text] [Related]
3. Comorbid migraine is associated with a negative impact on quality of life in patients with major depression.
Hung CI; Liu CY; Fuh JL; Juang YY; Wang SJ
Cephalalgia; 2006 Jan; 26(1):26-32. PubMed ID: 16396663
[TBL] [Abstract][Full Text] [Related]
4. The impact of anxiety and migraine on quality of sleep in patients with major depressive disorder.
Hsu SC; Wang SJ; Liu CY; Juang YY; Yang CH; Hung CI
Compr Psychiatry; 2009; 50(2):151-7. PubMed ID: 19216892
[TBL] [Abstract][Full Text] [Related]
5. [Association between health related quality of life and severity of depression in patients with major depressive disorder].
Cao Y; Li W; Shen J; Zhang Y
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2011 Feb; 36(2):143-8. PubMed ID: 21368424
[TBL] [Abstract][Full Text] [Related]
6. Rapid improvement of depression and quality of life with escitalopram treatment in outpatients with breast cancer: a 12-week, open-label prospective trial.
Park HY; Lee BJ; Kim JH; Bae JN; Hahm BJ
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Mar; 36(2):318-23. PubMed ID: 22142651
[TBL] [Abstract][Full Text] [Related]
7. Migraine: a missing link between somatic symptoms and major depressive disorder.
Hung CI; Liu CY; Cheng YT; Wang SJ
J Affect Disord; 2009 Sep; 117(1-2):108-15. PubMed ID: 19167091
[TBL] [Abstract][Full Text] [Related]
8. The impact of migraine on patients with major depressive disorder.
Hung CI; Liu CY; Juang YY; Wang SJ
Headache; 2006 Mar; 46(3):469-77. PubMed ID: 16618265
[TBL] [Abstract][Full Text] [Related]
9. Health-related quality of life in a clinical trial of ECT followed by continuation pharmacotherapy: effects immediately after ECT and at 24 weeks.
McCall WV; Rosenquist PB; Kimball J; Haskett R; Isenberg K; Prudic J; Lasater B; Sackeim HA
J ECT; 2011 Jun; 27(2):97-102. PubMed ID: 21206285
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
[TBL] [Abstract][Full Text] [Related]
11. Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: an open label study.
Akkaya C; Sivrioglu EY; Akgoz S; Eker SS; Kirli S
Hum Psychopharmacol; 2006 Jul; 21(5):337-45. PubMed ID: 16856215
[TBL] [Abstract][Full Text] [Related]
12. Quality of life outcomes among patients with depression after 6 months of starting treatment: results from FINDER.
Reed C; Monz BU; Perahia DG; Gandhi P; Bauer M; Dantchev N; Demyttenaere K; Garcia-Cebrian A; Grassi L; Quail D; Tylee A; Montejo AL
J Affect Disord; 2009 Mar; 113(3):296-302. PubMed ID: 18603303
[TBL] [Abstract][Full Text] [Related]
13. Comorbidities and factors related to discontinuation of pharmacotherapy among outpatients with major depressive disorder.
Hung CI; Wang SJ; Liu CY; Hsu SC; Yang CH
Compr Psychiatry; 2011; 52(4):370-7. PubMed ID: 21683174
[TBL] [Abstract][Full Text] [Related]
14. Quality of life and psychiatric co‑morbidity in Indian migraine patients: a headache clinic sample.
Sharma K; Remanan R; Singh S
Neurol India; 2013; 61(4):355-9. PubMed ID: 24005724
[TBL] [Abstract][Full Text] [Related]
15. Validation of the Depression and Somatic Symptoms Scale by comparison with the Short Form 36 scale among psychiatric outpatients with major depressive disorder.
Hung CI; Wang SJ; Liu CY
Depress Anxiety; 2009; 26(6):583-91. PubMed ID: 19242983
[TBL] [Abstract][Full Text] [Related]
16. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
17. Migraine predicts self-reported muscle tension in patients with major depressive disorder.
Hung CI; Liu CY; Chen JJ; Wang SJ
Psychosomatics; 2008; 49(6):502-10. PubMed ID: 19122127
[TBL] [Abstract][Full Text] [Related]
18. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
19. Relief of depression and pain improves daily functioning and quality of life in patients with major depressive disorder.
Lin CH; Yen YC; Chen MC; Chen CC
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Dec; 47():93-8. PubMed ID: 23989033
[TBL] [Abstract][Full Text] [Related]
20. The impacts of migraine and anxiety disorders on painful physical symptoms among patients with major depressive disorder.
Hung CI; Liu CY; Chen CY; Yang CH; Wang SJ
J Headache Pain; 2014 Nov; 15(1):73. PubMed ID: 25382691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
